Story perspectives

New Combination Therapy Shows Promise for Prostate Cancer

10/15/2025

Summary

Story summary

The Institute of Cancer Research, London researchers have identified a new treatment for advanced prostate cancer that could benefit about 40% of patients.
The approach combines fadraciclib, ipatasertib, and capivasertib to target MCL1 and AKT.
Lab studies show the combination slows tumor growth and kills cancer cells, especially in PTEN-loss/PI3K-activated tumors.
Clinical trials are anticipated soon as researchers seek funding to advance this treatment option.

1 of 1

Story summary

The Institute of Cancer Research, London researchers have identified a new treatment for advanced prostate cancer that could benefit about 40% of patients.
The approach combines fadraciclib, ipatasertib, and capivasertib to target MCL1 and AKT.
Lab studies show the combination slows tumor growth and kills cancer cells, especially in PTEN-loss/PI3K-activated tumors.
Clinical trials are anticipated soon as researchers seek funding to advance this treatment option.